Zhen Su, MD MBA

We are pleased to announce presentations of four of our clinical studies at the American Society of Clinical Oncology annual congress at Chicago. Our presentations this year include data of investigational drugs olverembatinib in patients with SDH deficient gastrointestinal stromal tumor (GIST), an indication that currently has no effective treatment; lisaftoclax in patients with acute myeloid leukemia (AML) and in patients with Waldenstrom macroglobulinemia (WM), as well as those of APG-2449 in patients with non-small cell lung cancer (NSCLC). We remain committed to bring novel and effective therapies for patients with cancers. We are currently conducting more than 40 clinical trials including 5 global registrational phase III trials in the US, Australia, Europe, and China. #ASCO #cancer #cancerresearch #drugdevelopment https://lnkd.in/eBxbAyuR

26

1 Comment

The countdown is on. Next week, I'm heading to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24). It's one of the most significant events in the oncology world, bringing together a global community of researchers, clinicians, advocates, and patients in the fight against cancer. For me, #ASCO24 is more than just a conference; it's a chance to: - Dive into the Latest Research: Thousands of abstracts will be presented, showcasing cutting-edge advancements across all aspects of cancer care. I'm eager to learn about new therapies, diagnostic approaches, and breakthroughs that can transform patients' lives. Discussing the evolving landscape of cancer treatment is crucial for staying updated on the latest developments and best practices in patient care. - Connect with Experts: Meeting and exchanging ideas with leading oncologists, scientists, and industry innovators is an invaluable experience. It fosters collaboration and fuels inspiration for advancing cancer care. - Share Our Recent Developments: Zephyr AI team will present a poster and share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data." Abstract # 5583 / Poster Bd # 454, presented by Emily Vucic et al., June 3rd, 9 am—12 pm: https://lnkd.in/g8wKqB8v In the meantime, what are you most interested in learning about from #ASCO24? Share your thoughts and questions. See you in Chicago!

28

1 Comment

Value-based payment arrangements are crucial for expanding patient access to cell and gene therapies. That’s why I am in Washington, DC, to advocate for the Medicaid Value-based Payments for Patients (MVP) Act at the Alliance for Regenerative Medicine’s Cell & Gene Congressional Fly-In July 15-16. #CGFlyIn24 #MVPACT #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #policy #valuebasedpayments #patientaccess #biotech #biotechnology #lifescience #lifesciences #advocacy #payments #congressionalsupport Erica Cischke #facilitatepatientaccess #removebarriers

22

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference   • Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C. difficile Infection (CDI) • Results consistent with those shown in earlier human volunteer studies and Phase 2a studies • Preservation and increased concentrations of beneficial Firmicute (Bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated  • Actinobacteria and Bacteroides preservation also confirmed using quantitative analysis   https://lnkd.in/eseFt8GZ   #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci

13

🔬 Remember the evidence-based medicine "ice berg"? Just talked with Evotec partners about how our patient-molecular database and the multi-omics approach in the human setting is critical for precise disease understanding. This reminded me of a 2022 paper by Vivek Subbiah, MD. It highlights the integration of wearable tech, data science, and machine learning in transforming evidence-based medicine - and, from my perspective, lays out a path of where drug discovery needs to go as well, based on longitudinal, "deep" molecular disease data sets. Read the paper here: https://lnkd.in/dKM8gBau.

65

Atossa Therapeutics announces an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Previous in silico and preclinical research determined a strong, clinically relevant, anti-tumor effect when combining the two therapies. “The work we are doing with Weill Cornell is designed to validate the in silico modeling in well-established cell culture models of breast cancer. Once we have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late-line metastatic breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. Learn more: https://lnkd.in/ekad_hWY #clinicaltrial #breastcancer, https://lnkd.in/ev6gadb7

38

1 Comment

Olaf Stamm discusses key criteria to consider when establishing analytical studies for a biosimilar drug candidate to ensure its safety, efficacy, and similarity compared to the reference product in the this article. Discover more here: https://bit.ly/3XnHA0D

23

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO (the “Acquisition”), for a total equity value of $2.4 billion. The boards of directors of both companies have unanimously approved the transaction. Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. https://lnkd.in/dY_hDwFT

10

💬💡 We spoke with Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer at Genmab, about the company’s key achievements and its focus on innovative solutions in antibody therapeutics! Since its establishment in 1999, Genmab has not only expanded its reach globally but has also spearheaded transformative therapies that have redefined cancer treatment and addressed other critical illnesses. ➡️ Read the full interview with Tahi Ahmadi to learn more about Genmab's strategic vision, technological advancements, and the next frontier in antibody research: https://buff.ly/4bcg368 #ClinicalTrials #Antibodies #Antibody #Biologics #ClinicalResearch #Biologic #ProteinTherapeutic #AntibodyDrug

4

Delighted to have joined the OnHelix 2024 panel session on "New Horizons for Therapeutic Modalities". We explored a range of topics, and here are the main points I took away: 🤝 Multi-modality synergies 🤝 On the panel, we all agreed on the need for a diverse and comprehensive toolkit of different modalities, as there is no silver bullet. I would go one step further and say that different modalities can and should be combined to achieve greater impact. Think of mRNA (mRNA-4157 from Moderna) + antibody (Keytruda from Merck) for resected melanoma treatment. mRNA-4157 is a personalized neoantigen therapy that encodes up to 34 neoantigens derived from the patient's tumor mutational profile. When administered, these neoantigens are processed and presented by the body’s cells, triggering a tailored immune response specifically against the tumor. Keytruda works by enhancing the immune system's ability to detect and attack cancer cells by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. The synergistic action has shown promising results, with the combination therapy showing an 18-month recurrence-free survival 17% higher than monotherapy (see link in the comments below). 📈 More data doesn't mean better AI 📈 The cost of generating data in life sciences is dropping thanks to automation, making vast amounts of data available for both discovery and process automation. This treasure trove of data can be used to train AI/ML models to understand multifactorial diseases, develop advanced therapeutics, and optimize manufacturing processes to achieve better quality and economics. However, data accuracy, completeness, and standardization remain critical issues. The integration of data from disparate sources, each using different data standards and lacking semantic consistency, poses significant challenges. I came across a paper where the authors describe in detail how integrating different data sources with poor consistency actually decreases model accuracy to such an extent that it's not worth combining these sources if they are not aligned (see link in the comments below). 🕑 Move fast, break things...sort of 🕗 While cell and gene therapy manufacturing costs are rightly prioritized, the impact of development time on the overall economics of therapeutic development is equally significant. This issue was a focal point of the panel discussion, where panelists shared firsthand experiences and underscored the sluggishness of the design-build-test-learn cycle for CGT therapeutic development. Certainly, there isn't a single dominant cause of the slowdown; rather, several bottlenecks combine to delay progress and drive up costs. But if you had to choose one, which major bottleneck do you face most frequently in the discovery phase of new CGT? #ONHelix24 #CGT #mRNA

33

3 Comments

News from Madrid!. Today, Oryzon hosted its 2024 General Shareholders Meeting in Madrid, providing an opportunity to engage with attendees in person, discuss market performance, and address future challenges. With a quorum representing 42.7% of the company's capital, shareholders were updated on our CNS and oncology programs.We proudly shared details of our ongoing collaboration with the National Cancer Institute (NCI) through our Cooperative Research and Development Agreement (CRADA). We also highlighted the promising results from our Phase 2 trial in Borderline Personality Disorder (BPD), discussing our ongoing interactions with the FDA regarding our End-of-Phase 2 (EoP2) meeting. If the FDA approves our proposed Phase 3 trial design, Oryzon will become the first company to initiate a Phase 3 trial for BPD. All resolutions were approved by the shareholders, with favorable votes ranging from 79% to 96%. A particularly significant resolution authorized a potential capital increase of up to 100 million euros, delegating to the Board of Directors the authority to set the date, determine the issue price, and establish other conditions. This capital increase will help fund a potential Phase 3 trial in BPD and support our ongoing Phase 2 trial in schizophrenia https://lnkd.in/dgjHH-v4 #LSD1 #Borderline_personality #schizophrenia #epigenetics #personalizedmedicine #AML #SCLC #vafidemstat #iadademstat

52

2 Comments

A year ago, we launched a comprehensive effort to address a leading public health crisis - cardiovascular disease. Our mission was urgent - to cut the number of heart attacks and strokes in the U.S. in half by 2030. Working with industry leaders, organizations, and institutions, we’ve already made remarkable strides to reach this goal by the end of the decade. Here are a few highlights: Combining the collective leadership of experts and organizations across the country, we’ve launched a number of educational initiatives to increase awareness and activation around LDL (“bad”) cholesterol, one of the most modifiable risk factors of cardiovascular disease. These include a public service announcement, free testing services, new tools and resources for underserved communities and the launch of our “Living in the Red" campaign. Together with the LATTICE ™ Consortium, we leveraged implementation science to improve cardiovascular care across 60 institutions and 6,000 private practice clinics, reaching more than 4 million patients. We also brought together top cardiovascular organizations and experts through the LDL-C Action Summit and Local Roundtables to bridge the gap between knowledge and action in managing LDL-C. We helped more than 12,000 people obtain LDL-C tests to learn more about their bad cholesterol levels and be informed when they talk to their doctor about their cardiovascular health. None of this would be possible without the collective force of the nation’s foremost leaders in cardiovascular care, and the dedication of our exceptional Amgen colleagues. Huge shoutout to David Reese, Murdo Gordon, and Ian Thompson, who have supported our teams with vision and commitment. Enormous appreciation to Nerissa Gomes, Bethany Kalich, Jyothis George, Michelle Carrillo Erika Funck, FNP, RN, MBA, and Darby Sedighan, among many others who have supported this bold ambition since the beginning. Together, we are making a tangible difference in cardiovascular health by continuously raising awareness about the importance of LDL-C testing. #MyCompany

274

10 Comments

In an era where medicine is as complex as the diseases it aims to treat, involving patients isn't just beneficial—it's imperative. Patient insights drive the development process, from initial design to regulatory approval. This approach isn't just about compliance; it's about crafting therapies that genuinely help those who need it. When patients are the cornerstone of our development strategy, it leads to faster trial enrollments, particularly in rare diseases. It helps us navigate the regulatory landscape more effectively by aligning early with patient needs and expectations.

23

Affinia is proud to announce new preclinical data on our novel AAV capsids for genetic cardiomyopathies and diseases of the CNS such as #ALS, as well as our high-yield manufacturing process being presented at #ASGCT24. Of note, our novel cardiotropic capsids transduce more than 90% of cardiomyocytes in NHPs and detarget the liver and DRG and show safety and efficacy in a mouse model of cardiac dysfunction. And, our novel BBB-penetrant capsid transduces more than 50% of neurons in NHPs across spinal cord, cortex, and deep-brain regions and detargets the liver and DRG, and shows greater than 50% reduction of Ataxin-2, a gene believed to be involved in sporadic #ALS. Read more in our press release https://bit.ly/4aknE1k #GeneTherapy #rationallydesignedcapsids

174

1 Comment

The latest news from ACURX Pharma on New to the Street: https://lnkd.in/e4iXg3hD Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). #acurxpharma #acxp #nasdaq 

24

Producing consistent results is the most effective way to get funding and get published. Get consistent results by using a Singulator for your sample prep.

9

❗INTERIM PHASE 1 UPDATE❗ 📍 13 patients dosed, beating enrollment expectations We are thrilled to share an exciting update from our ongoing Phase 1 clinical trial for CYT-108. As of now, 13 patients have been successfully 💉 dosed out of the 20 total participants, surpassing our initial enrollment expectations. Even more encouraging is the fact that no adverse events have been reported so far. We anticipate having the full Phase 1 clinical report 📖 available in Q3/Q4 2025. This progress brings us one step closer to our goal of providing a groundbreaking treatment for osteoarthritis. We extend our deepest gratitude 🤝 our shareholders for your unwavering support and belief in our mission. Your investment has been instrumental in reaching this pivotal milestone, and we are committed to maximizing shareholder value by efficient capital allocation. Approximately 70% of all investor dollars 💵 are spent directly on research and development of CYT-108.   ❤️ Thank you once again for your continued support. Together, we can usher in a future where osteoarthritis is a thing of the past. invest.cytonics.com #biotechnology #arthritis #clinicaltrials #drugdevelopment #investing

28

3 Comments

Pharma news.... 💉Novo Nordisk Wegovy won approval in China and in response to the nod, Novo’s share price increased by 3%. (Pictured) 🧠 AbbVie hits another problem as Duopa successor in Parkinson's was rejected again after FDA flags 3rd-party manufacturer issues. (https://lnkd.in/ezmrnYhb) 🧬 Kite Pharma has partnered with Cytiva to develop a new cell therapy manufacturing platform, which was rolled out last month. (https://lnkd.in/eeWUS66v) 🫁 Verona Pharma's Ohtuvayre earns FDA approval to treat chronic obstructive pulmonary disorder (COPD). (https://lnkd.in/eWDCyxnT) 💲 The high court blocked a multi-billion-dollar bankruptcy agreement for Purdue Pharma and its founding family. The deal, $6 billion to the company's bankruptcy estate in exchange for immunity from civil lawsuits related to the nationwide opioid crisis. (https://lnkd.in/eQ9cF9Ee) Follow for more 🔔 🧬

11